Eli Lilly: positive phase III results in migraine
(CercleFinance.com) - On Monday Eli Lilly reported "positive" results for Emgality, its preventive treatment of migraine in patients who are typically struggle with this type of drug.
Results from a Phase III study that enrolled 462 patients met the primary endpoint of the clinical trial, as well as its secondary endpoint, Lilly said in a statement.
According to medical literature, over 40% of patients using migraine-preventative medications do not see any improvement in their state or regularly change their treatment.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
Results from a Phase III study that enrolled 462 patients met the primary endpoint of the clinical trial, as well as its secondary endpoint, Lilly said in a statement.
According to medical literature, over 40% of patients using migraine-preventative medications do not see any improvement in their state or regularly change their treatment.
Copyright (c) 2019 CercleFinance.com. All rights reserved.